Aug 02, 2021 / 12:30PM GMT
Kath Gallagher - Avidity Biosciences, Inc. - SVP, Communications & IR
Good morning, everyone. I'm Kath Gallagher, Senior Vice President of Communications and Investor Relations at Avidity. Thank you so much for joining today for Volume 2 of our investor and analyst event series.
Before we get started, we want to remind everyone that we will be making forward-looking statements based on our current expectations that are subject to and covered by the safe harbor protections provided under the Private Securities Litigation Reform Act of 1995, including statements about the initiation of clinical trials.
These forward-looking statements are not a guarantee of performance, and Avidity's actual results may differ materially from these forward-looking statements as a result of various important factors, including those discussed in the risk factor sections of Avidity's SEC filings, including our recently filed 10-K, 10-Q and S-3 ASR. These statements are time sensitive and represent Avidity's views as of today's date, and we disclaim any obligations to update these forward-looking
Avidity Biosciences Inc Phase 1/2 AOC1001 Clinical Data Update Call Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers